Christopher Fenimore, Regeneron Pharmaceuticals CFO, on the record

Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures

Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron, Regeneron PharmaceuticalsRegeneron Reports Second Quarter 2026 Financial and Operating Results · July 30, 2026 · source: sec.gov

In context

"Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures," said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron

Verbatim from the company's earnings release at sec.gov, accessed 2026-09-26.

Said July 30, 2026 in the Regeneron Reports Second Quarter 2026 Financial and Operating Results. Regeneron Pharmaceuticals's CFO record: Regeneron Pharmaceuticals on the record. We publish quotes as the company released them and add no view on the company's results or shares.